A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer

The immunohistochemical determination of HER-2 to identify patients with advanced breast cancer candidates for Trastuzumab treatment proved neither accurate nor fully reliable, possibly because none of the current reagents detects the specific antigenic site target of Trastuzumab. To circumvent this...

Descripción completa

Detalles Bibliográficos
Autores principales: Bussolati, G, Montemurro, F, Righi, L, Donadio, M, Aglietta, M, Sapino, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361978/
https://www.ncbi.nlm.nih.gov/pubmed/15812476
http://dx.doi.org/10.1038/sj.bjc.6602507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361978/
https://www.ncbi.nlm.nih.gov/pubmed/15812476
http://dx.doi.org/10.1038/sj.bjc.6602507

Ejemplares similares